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Background: The disparity in outcomes of CIED implantations between sexes has been 
previously demonstrated in device-specific cohorts (e.g. implantable cardioverter 
defibrillators (ICD)). However, it is unclear whethr sex differences are present with all 
types of CIED and, if so, what the trends of such differences were in recent years.  
Methods: Using the National Inpatient Sample, all hospitaliz tions between 2004 and 2014 
for de novo implantation of permanent pacemakers (PPM), cardiac resynchronization 
therapy with or without a defibrillator (CRT-D and CRT-P, respectively) and ICD were 
analyzed to examine the association between sex and in-hospital acute complications of 
CIED implantation. 
Results: Out of 2,815,613 hospitalizations for de novo CIED implantation, 41.9% were 
performed on women. Women were associated with increased adjusted odds of adverse 
procedural complications (major adverse cardiovascul r complications: 1.17 [1.16, 1.19], 
bleeding: 1.13 [1.12, 1.15], thoracic: 1.42 [1.40, 1.44], cardiac: 1.44 [1.38, 1.50]), while the 
adjusted odds of in-hospital all-cause mortality compared to men was 0.96 [0.94, 1.00]. The 
odds of adverse complications in the overall CIED cohort were persistently raised in women 
throughout the study period, whereas similar odds of all-cause mortality across the sexes 
were observed throughout the study period.   
Conclusion: In a national cohort of CIED implantations we demonstrate that women are at 
an overall higher risk of procedure-related adverse ev nts compared to men, but no 
increased risk of all-cause mortality. Further studies are required to identify procedural 








Little is known about sex differences in procedural outcomes of CIED implantations. The 
present study examined trends of sex differences in outcomes over an eleven-year period in a 
national cohort of CIED implantations. Women were shown to be at a higher risk of adverse 





The rates of utilization of cardiac implantable electronic devices (CIED), including 
permanent pacemakers (PPM), cardiac resynchronization therapy with pacemakers (CRT-P) 
or defibrillators (CRT-D) and implantable cardioverter defibrillators (ICD) continue to grow. 
1 Despite advances in implantation techniques, CIED systems (leads and devices) and 
proficiency of operators, the rate of major complications remains significant. 2, 3  
Previous studies have either examined the overall trends of CIED implant-related 
complications without differentiation between sexes, or the overall effect of sex on outcomes 
without analysis of historical trends. 2, 4-7 However, to the best of our knowledge no study 
has compared the trends in outcomes of CIED implantations between sexes. Women are 
more prone to major complications following CIED implantation due to anatomical 
differences such as smaller and thinner vessels, smaller chest cavities and lower body weight. 
8, 9 Although these factors are less likely to change ov r the years, increasing awareness of 
complication risk and advancements in procedural techniques and skills to deal with these 
anatomical challenges could influence the trends of outcomes. Furthermore, little is known 
about sex differences in procedural outcomes of different device groups. Complex device 
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implantation is often associated with longer procedural time and more prolonged lead 
manipulation, which is known to predispose to more v nous damage, secondary 
inflammation and infection.10, 11 It is possible that sex differences in the susceptibility to 
these processes exist.12  
The present study examined the temporal trends of de novo CIED implantation 
outcomes and according to sex and CIED type (PPM, CRT and ICD) in a nationwide cohort 




The National Inpatient Sample (NIS) is the largest publicly available all-payer 
database of hospitalized patients in the United States nd is sponsored by the Agency for 
Healthcare Research and Quality as a part of the Healthcare Cost and Utilization Project 
(HCUP).13 Further information about the structure and validation of NIS is available in 
Appendix A of the Supplemental Material.  
 
Study Design and Population 
All adults (aged ≥18 years) undergoing de novo CIED implantation (PPM, CRT-P, 
CRT-D, and ICD) during hospitalization were included in this study.  We excluded any 
records with missing data (<3% of full dataset) on the following variables: age, sex, elective 
admission, primary expected payer, median household income and hospital bed size and 
location. A flow diagram illustrating the inclusion and exclusion process in the present study 
is presented in Figure S1 (Supplemental Material).  Cases excluded due to missing variables 
represented less than 3% (n=18,321) of the original dataset. The final study cohort was 
stratified by sex into males and females. 
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CIED procedures, patient characteristics, comorbidities, and clinical outcomes were 
extracted using the International Classification of Diseases, ninth revision (ICD-9), procedure 
and diagnosis codes provided in the supplements (Table S1 in Supplemental Material); 
procedure-related bleeding, cardiac complications (composite of cardiac tamponade, 
hemopericardium, pericardial effusion and pericardiocentesis) and thoracic complications 
(composite of acute pneumothorax or hemothorax, with or without drainage, or thoracic 
vascular injury). Procedure-related bleeding was defined as any post-procedural hemorrhage 




The primary outcomes were in-hospital adverse events, including major acute 
cardiovascular events (MACE), all-cause mortality and procedural-related complications 
(bleeding, thoracic and cardiac) between sexes according to type of CIED implanted. In-
hospital MACE was defined as a composite of all-cause mortality, cardiac complications, 
thoracic complications and device-related infection.  
 
Statistical Analysis 
Statistical analysis was performed using SPSS version 24 (IBM Corp, Armonk, NY). 
The use of sampling weights is required because the design of the study means that different 
observations may have different probabilities of selection. For calculation of national 
estimates and correct variances, sampling weights for each individual discharge that were 
provided by the AHRQ were used in SPSS. Continuous variables are presented as medians 
with interquartile range (IQR) and were compared using the Kruskal-Wallis test. Categorical 
variables are presented as percentages and were analyzed using the chi-squared (X2) test. 
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Trend analysis was performed using linear regression m deling with the inclusion of time 
(years) as a covariate for assessing sex differences i  type of device use over time, and by 
assessing the interaction between sex and time (years) in logistic regression analysis for 
clinical outcomes. 
Multiple logistic regression models were constructed o identify the adjusted odds 
ratio (aOR [95% confidence interval]) of procedure-related adverse outcomes in women 
using men as the reference category, adjusting for di ferences in covariates that may directly 
influence in-hospital outcomes (Appendix B in Supplemental Material).  
 
Results 
A total of 569,061 records of de novo CIED implantations between 2004 and 2014 
were identified, which corresponded to 2,815,613 hospitalizations. The percentage of women 
in the total cohort was 41.9%. The prevalence of women amongst those undergoing CIED 
implantation increased throughout the years in all device subgroups (CRT-P, CRT-D and 
ICD) except PPM where proportions were similar over the study period (PPM: 49.5% in 
2004 to 50.7% in 2014) (Figure 1).  
We observed several key differences in patient characte istics between sexes in the 
overall cohort (Table 1). Overall, women were older with fewer elective admissions and a 
significantly lower prevalence of cardiovascular risk factors such as dyslipidemia, smoking 
history, history of IHD, previous AMI and PCI, life-threatening arrhythmias such as 
ventricular fibrillation and tachycardia, renal failure, as well as shock. In contrast, women 
had a higher prevalence of atrial fibrillation, hypothyroidism, hypertension, previous CVA 
and deficiency anemias. The differences in characteistics between sexes were generally 
consistent across different device groups, however, some exceptions were observed. (Tables 
S2-4 in Supplemental Material) For example, the prevalence of atrial fibrillation was lower in 
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women undergoing CRT-D and ICD compared to men, and there was no difference in the 
prevalence of previous CVA between sexes in patients u dergoing CRT-D implantation.  
 
In-hospital adverse outcomes 
  The overall crude rate of MACE in the entire CIED cohort was 5.0%, primarily 
driven by thoracic complications (3.0%) followed by all-cause mortality (1.0%), device 
related infection (0.9%) and cardiac complications (0.4%), while the rate of procedure-related 
bleeding was 2.9%. (Table 2) The rates of all adverse vents were generally higher amongst 
patients undergoing CRT-P implantation compared to all ther device groups. (Table 3)  
In the total CIED cohort, all in-hospital adverse events occurred at a higher crude rate 
in women compared to men (MACE: 5.6% vs. 4.5%; all-c use mortality: 1.0% vs. 0.9%; 
procedure-related bleeding: 3.2% vs. 2.7%; thoracic complications: 3.8% vs. 2.4%; and 
cardiac complications: 0.5% vs. 0.3%), except device-related infections that were higher in 
men (1.1% vs. 0.6%). (Table 2, Figure 2a) Although this pattern was generally consistent 
across all device subgroups, there were exceptions such as the lower rates of MACE (6.6% 
vs. 7.3%), all-cause mortality (1.0% vs. 1.6%) and procedure-related bleeding (3.3% vs. 
3.6%) in women undergoing CRT-P implantation, and the lower rate of all-cause mortality 
(0.6% vs. 0.8%) in women undergoing CRT-D implantation. (Table 3, Figure 2b) 
In multivariate analysis of the overall CIED cohort, women were at significantly 
increased odds of MACE (aOR 1.17 [1.16, 1.19]), procedure-related complications (aOR 
bleeding: 1.13 [1.12, 1.15], thoracic: 1.42 [1.40, 1.44] and cardiac: 1.44 [1.38, 1.50]). (Table 
4, Figures 3a and 3b) There were statistically significant differences in odds of adverse events 
in women between device types. Although the odds of MACE and procedure-related 
complications were generally higher in women compared to men, women were associated 
with lower odds of MACE (aOR 0.91 [0.85, 0.97]) and o statistically significant difference 
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in odds of procedure-related complications (aOR bleeding: 1.01 [0.92, 1.11], thoracic: 1.04 
[0.95, 1.12] and cardiac: 1.06 [0.84, 1.35]) in the CRT-P group.  
No statistically significant difference in all-cause mortality was observed between 
sexes in the total CIED cohort (aOR 0.96 [0.94, 1.00])  (Table 4, Figure 3b) The strongest 
predictors of all-cause mortality in the total CIED cohort included a history of cardiac arrest 
(OR 4.99 [4.81, 5.17]), VT (OR 1.34 [1.29, 1.39]), VF (OR 1.44 [1.36, 1.52]), coagulopathy 
(OR 2.33 [2.2, 2.46]) or heart failure (OR 2.43 [2.36, 2.50]), and all-cause infection during 
admission (OR 5.87 [5.68, 6.07]) (p<0.001 for all).  Within the device subgroups, women 
were associated with no statistically significant difference in odds of all-cause mortality in 
the PPM and ICD groups (aOR 1.01 [0.98, 1.05] and 1.05 [0.97, 1.13], respectively), and 
reduced odds of all-cause mortality in the CRT groups (aOR CRT-P:  0.70 [0.60, 0.82] and 
CRT-D: 0.72 [0.66, 0.80]) compared to men.  
A trend analysis of the odds of adverse events over th  study period shows 
persistently increased odds of MACE, bleeding thoracic nd cardiac complications in women 
from 2004 to 2014, with a rising trend of these complications in women. (Figures 4a and 4b, 
p<0.001) In contrast, while the adjusted odds of all-c use mortality in women were generally 
non-significant compared to men throughout the study period, the trend analysis highlighted 
that there was a significant trend towards lower risk of mortality in women compared to men. 
(Figure 4b, p<0.001)  
Discussion 
 The present study is the largest study to examine sex differences in procedural 
outcomes of CIED implantations, and the first to report the trends of these outcomes in a 
nationwide cohort of US hospitalizations. Over an 11-year horizon, we observe a rise in the 
prevalence of women amongst patients undergoing CIED implantations across all device 
types except PPM. Our findings demonstrate increased odds of in-hospital implant-related 
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complications (bleeding, thoracic and cardiac) in women, both in the overall CIED cohort as 
well as in individual CIED types other than CRT-P, and that this risk has persisted over the 
years. We also find that there was no difference in all-cause mortality between sexes in 
patients undergoing PPM and ICD implantations, while women undergoing CRT implant, 
with or without a defibrillator, were associated with reduced odds of all-cause mortality 
compared to men. The observed similarity in odds of all-cause mortality between sexes in the 
overall cohort was persistent over a decade. 
 Previous studies have demonstrated an association between sex and adverse outcomes 
in patients undergoing cardiovascular procedures such as coronary artery bypass grafting 14, 
percutaneous coronary intervention 15-17 and catheter ablation 18. Although there is 
evidence to suggest worse outcomes in women after CIED implantations, it is derived from 
studies that have been subject to limitations such as the restriction of analysis to specific 
devices (e.g. ICD or PPM only), old registries (prior to 2010) or specific cohorts (e.g. heart 
failure) and, therefore, are not generalizable from a national or contemporary perspective. 5, 
6, 19-23 Furthermore, the current evidence does not inf rm operators of the differences in 
trends of outcomes between sexes in recent years. For example, one recent study by Moore et 
al. examined sex differences in acute complications of CIED implants on a national level in 
over 80,000 CIED implantations in Australia and New Zealand.4 Their analysis looked at the 
effect of sex on procedural outcomes in the overall CIED cohort without comparison between 
CIED subtypes in multivariate analysis for in-hospital outcomes. Another study showed no 
difference in in-hospital mortality between sexes, in line with our findings, although this was 
also performed in the overall cohort without stratification of mortality by device type.4  
Moore et al. reported increased odds of in-hospital complications (composite of death, 
reoperation including pleural/pericardial drainage, post-procedural shock and infective 
endocarditis) in women undergoing any CIED implant (OR: 1.20 [1.11, 1.30]), although  
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their analysis did not differentiate between CIED types except for pleural/pericardial 
drainage, despite the contrast in patient characteristics and operative risk between groups 
undergoing different devices. 4 Similarly, a national analysis of CIED implantations in 
Denmark between 2010 and 2011 demonstrated an increased risk of major complications in 
women (risk ratio: 1.4 [1.2-1.8]), although their analysis was not stratified according to type 
of CIED. 6  Our analysis confirms previous reports of increased odds of complications in 
women (bleeding, thoracic and cardiac) and also demonstrates this risk in all device types 
except CRT-P where the odds of complications were non-significant between sexes or lower 
in women. Furthermore, the present study is the first to report temporal trends of sex 
difference in procedure-related complications, and demonstrates a rising trend of in-hospital 
complications (bleeding, thoracic and cardiac) in women undergoing CIED implantations.  
 Our analysis shows no difference in all-cause mortality between sexes throughout the 
study period in the overall cohort, except in CRT groups, where all-cause mortality was 
lower in women. However, the interaction between sex and year indicated a trend towards 
lower risk of mortality in women compared to men. The reduced mortality in women 
undergoing CRT implantation could be explained by their more favorable CRT response, 
which has been previously shown to reduced their as lower risk of all-cause mortality 
compared to men in a meta-analysis (hazard ratio: 0.67 (0.61–0.74), p=0.03).24 The lack of 
difference in all-cause mortality between sexes despit  increased odds of procedural 
complications in women may suggest that a significant proportion of deaths are not 
procedure-related. We were unable to explore this further since our dataset does not capture 
the cause of death. The majority of previous studies r porting outcomes of CIED 
implantation have also focused on all-cause mortality, but a Danish registry of 5942 patients 
undergoing CIED implantation only attributed 1 out f 327 deaths (0.3%) within 6 months to 
procedure-related causes.6 Previous studies that looked at sex differences demonstrated 
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similar findings to our study with respect to all-cause mortality, although they were derived 
from combined analyses of all CIED types, or from specific device cohorts (e.g. ICD only), 
without looking at sex differences in different device groups.5, 25 Peterson et al. also reported 
no difference in all-cause mortality (in-hospital 0.42 vs. 0.41%, p=0.505) between sexes in a 
NCDR registry analysis of 161,470 patients undergoin  ICD implantation in the United 
States between 2006 and 2007, as did MacFadden et al. in heir provincial registry analysis of 
ICD implants between 2007 and 2010 (1 year mortality hazard ratio: 1.00 [0.64,1.55], 
p=0.99).5, 25 The Australian/New Zealand cohort showed no difference in in-hospital 
mortality between sexes, in line with our findings. although this was also performed in the 
overall cohort without stratification of mortality by device type.4  
 The rising trend of in-hospital complications in women (bleeding, cardiac and 
thoracic) over our study period is particularly conerning in view of the advancements in 
implantation techniques, such as use of ultrasound, as well as more electrophysiologists 
performing this procedure that receive dedicated 1 to 2 years training (as opposed to 
cardiologists and surgeons), and suggests that sex is an independent predictor of outcomes. 
26 The higher risk of thoracic and cardiac complications in women could be explained by 
anatomical differences such as smaller thoracic cavity size, smaller subclavian/axillary vein 
diameters increasing the risk of pneumothorax; and thinner right ventricle walls as well 
smaller size of coronary sinuses increasing the likelihood of cardiac perforation. 8, 9, 27, 28 It 
is possible that use of cephalic vein cutdown, ultrasound of vascular access, careful use of 
fluoroscopy or potentially ultrasound to guide true septal placement of right ventricular leads 
and his bundle pacing in lieu of coronary sinus or traditional right ventricular apical pacing 
may decrease this risk. In the right clinical scenarios, use of subcutaneous ICD instead of the 
traditional transvenous ICD or leadless pacemakers instead of the traditional single lead 
pacemakers, may further mitigate these risks. Whilst we observed a trend towards worse 
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outcomes in procedure-related complications (bleeding, thoracic and cardiac) in the CRT-P 
group, these were not statistically significant that could be due to its small sample size (2.3% 
of total CIED cohort) compared to all other device subgroups, which may mask any sex 




There are several limitations to our study. First, the administrative nature of the NIS 
database, as with any such database has limitations around the accuracy of coding with no 
external validation. However, the use of administrative data has been previously validated for 
the purpose of cardiovascular research 29, and for capturing CIED-related complications.30 
Furthermore, the NIS database has a comparable capture of patient demographics and 
superior geographic capture of hospitalizations in more than 25 diagnosis groups in 
comparison to large multistate electronic health reco d databases.31 Secondly, since the NIS 
dataset does not provide information on pharmacotherapy, indication for each CIED device 
(e.g. type of arrhythmia and primary vs. secondary p evention in CRT-D and ICD 
procedures), subtype of device wherever applicable (e.g. single versus dual chamber 
pacemaker, subcutaneous ICD, His-bundle pacemaker) nd operator experience, we were 
unable to adjust for the differences in these covariates between the study groups. However, 
pacemaker type and indication were shown to have an insignificant effect in a large analysis 
of ICD outcomes in women. 5 Furthermore, due to the observational nature of these data, the 
results should not be interpreted as causal, but rather relate to associations that require further 
research. Finally, the NIS dataset only reports in-hospital outcomes and, therefore, the 
present findings are not be applicable to longer term outcomes.  
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Conclusion 
 In our temporal analysis of almost 3 million hospitalizations for de novo CIED 
implantation over an 11-year period, we demonstrate hat women were at an increased risk of 
in-hospital adverse procedural outcomes compared to men, and that there has been a 
worsening trend in outcomes for women over the study period. Our findings also show no 
difference in the risk of all-cause mortality between sexes, although there was a trend towards 
a lower risk of death in women compared to men. These findings emphasize the need for 
further research to investigate the exact mechanisms of these sex differences and develop 
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Figure 1. Proportion of women undergoing CIED implantation procedures according to 
type of CIED (2004-2014) 
 
Legend: p-values are for trends 
 
Figure 2a. In-hospital outcomes of total CIED cohort according to sex 
 
Legend: p<0.001 for all outcomes; MACE: Composite of mortality, thoracic and cardiac 
complications, and device-related infection 
 
Figure 2b. In-hospital outcomes of CIED subtypes according to sex 
 
Legend: § non-significant; † p<0.05; ‡ p<0.001; ICD : automated implantable cardioverter-
defibrillator; CRT-P & CRT-D:  cardiac resynchronization therapy - pacemaker or - 
defibrillator, respectively; MACE : Composite of all-cause mortality, thoracic and cardiac 
complications, and device-related infection; PPM: permanent pacemaker. 
 
Figure 3a. Adjusted odds ratio (aOR) of major adverse cardiovascular events (MACE) 
in women (reference is men). 
 
Legend: *p<0.01; † p<0.001; ICD : automated implantable cardioverter-defibrillator; CRT-P 
& CRT-D:  cardiac resynchronization therapy - pacemaker or -defibrillator, respectively; 
MACE : Composite of all-cause mortality, thoracic and cardiac complications, and device-
related infection; PPM: permanent pacemaker. 
 
Figure 3b. Adjusted odds ratios (aOR) of all-cause mortality and procedure-related 
complications in women (reference is men) 
 
Legend: † p<0.001; § non-significant; ICD : automated implantable cardioverter-
defibrillator; CRT-P & CRT-D:  cardiac resynchronization therapy - pacemaker or - 
defibrillator, respectively; PPM: permanent pacemaker 
 
Figure 4a. Trend of adjusted odds ratios (aOR) of MACE in women compared with 
men (2004-2014)* 
 
Legend: *p<0.001 for trend; MACE : Composite of all-cause mortality, thoracic and cardiac 
complications, and device-related infection 
 
Figure 4b. Trend of adjusted odds ratios (aOR) of all-cause mortality and procedure-
related complications in women compared with men (2004-2014)* 
 
Legend: *p<0.001 for all 4 trends 
Table 1. Patient characteristics according to sex 
Variable/Group (%) Male (58.1) 
Female 
(41.9) Total p-value 
Number of weighted discharges 1637121 1178492 2815613 <0.001 
Type of CIED, %    <0.001 
PPM 53.2 74.7 62.2  
CRT-P 2.4 2.3 2.3  
CRT-D 16.7 8.7 13.3  
ICD 27.7 14.2 22.1  
Age (years), median (IQR) 73 (63, 81) 77 (68,84) 75 (65,82) <0.001 
Ethnicity, %    <0.001 
White 79.9 77.6 78.9  
Black 8.8 10.8 9.6  
Hispanic 6.4 6.6 6.5  
Asian/Pacific Islander 1.8 2.1 1.9  
Native American 0.5 0.5 0.5  
Other 2.6 2.3 2.5  
Elective Admission, % 33.5 26.9 30.8 <0.001 
Weekend admission, % 14.1 16.6 15.1 <0.001 
Primary expected payer, %    <0.001 
Medicare 71.2 78.6 74.3  
Medicaid 4.2 4.5 4.4  
Private Insurance 20.4 14.2 17.9  
Self-pay 1.9 1.3 1.7  
No charge 0.2 0.2 0.2  
Other 2.0 1.1 1.6  
Median Household Income 
(Percentile), % 
   <0.001 
0-25th 24.9 27.0 25.8  
26-50th 26.3 26.9 26.6  
51-75th 24.8 24.0 24.5  
Variable/Group (%) Male (58.1) 
Female 
(41.9) Total p-value 
76-100th 24.0 22.1 23.2  
Shock, % 1.5 1.2 1.4 <0.001 
All-cause infection, %* 2.5 2.4 2.5 0.198 
Cardiac Arrest, % 3.7 3.7 3.7 0.612 
Ventricular Tachycardia, % 20.1 10.2 16.0 <0.001 
Ventricular Fibrillation, % 3.8 2.5 3.2 <0.001 
Comorbidities, %     
Dyslipidaemia 43.9 39.7 42.1 <0.001 
Smoking 8.8 5.5 7.4 <0.001 
Atrial Fibrillation 36.0 41.3 38.2 <0.001 
Thrombocytopaenia 3.7 2.8 3.3 <0.001 
Previous AMI 16.9 8.8 13.5 <0.001 
History of IHD 57.6 37.5 49.2 <0.001 
Previous PCI 11.7 7.1 9.8 <0.001 
Previous CABG 18.5 7.5 13.9 <0.001 
Previous CVA 4.1 4.9 4.5 <0.001 
Family history of CAD 2.8 2.5 2.7 <0.001 
AIDS 0.1 0.0 0.1 <0.001 
Alcohol abuse 2.8 0.6 1.9 <0.001 
Deficiency anaemias 11.3 15.4 13.0 <0.001 
Chronic Blood loss anaemia 0.6 0.9 0.7 <0.001 
RA/collagen vascular 
diseases 
1.2 3.2 2.1 <0.001 
Heart Failure 46.3 40.2 43.8 <0.001 
Chronic pulmonary disease 19.1 19.1 19.1 0.103 
Coagulopathy 4.8 4.0 4.5 <0.001 
Depression 4.3 8.0 5.8 <0.001 
Diabetes 25.7 23.9 24.9 <0.001 
Diabetes with complications 4.6 4.4 4.5 <0.001 
Variable/Group (%) Male (58.1) 
Female 
(41.9) Total p-value 
Drug abuse 1.1 0.6 0.9 <0.001 
Hypertension 62.5 67.0 64.3 <0.001 
Hypothyroidism 7.6 20.0 12.8 <0.001 
Liver disease 1.2 1.0 1.1 <0.001 
Lymphomas 0.7 0.6 0.6 <0.001 
Fluid and electrolyte disturbances 15.3 20.7 17.5 <0.001 
Metastatic cancer 0.5 0.4 0.5 <0.001 
Other neurological disorders 5.4 6.9 6.0 <0.001 
Obesity 8.2 9.4 8.7 <0.001 
Paralysis 1.5 1.6 1.5 <0.001 
Peripheral vascular disease 9.8 7.6 8.9 <0.001 
Psychoses 1.5 2.1 1.8 <0.001 
Pulmonary circulation disorder 0.5 0.8 0.6 <0.001 
Renal failure (chronic) 17.0 14.7 16.0 <0.001 
Solid tumour without metastases 1.5 0.9 1.2 <0.001 
Valvular heart disease 1.2 1.7 1.4 <0.001 
Weight loss 1.9 2.3 2.0 <0.001 
Dementia 1.7 2.7 2.1 <0.001 
Hospital bed size, %    <0.001 
Small 8.5 9.2 8.8  
Medium 21.3 22.6 21.8  
Large 70.2 68.2 69.4  
Hospital Region, %    <0.001 
Northeast 21.5 21.1 21.4  
Midwest 23.3 24.0 23.6  
South 37.0 37.8 37.3  
West 18.1 17.1 17.7  
Location/ Teaching status, %    <0.001 
Variable/Group (%) Male (58.1) 
Female 
(41.9) Total p-value 
Rural 6.0 7.4 6.6  
Urban non-teaching 40.1 41.8 40.8  
Urban- teaching 53.9 50.8 52.6  


























*  MACE: Composite of mortality, thoracic complications, cardiac complications, and device-related infection.  
 
Variable/Group (% of cohort) Male (58.1) 
Female 
(41.9) Total p-value 
In-hospital MACE, %* 4.5% 5.6% 5.0% <0.001 
In-hospital all-cause mortality, % 0.9% 1.0% 1.0% <0.001 
In-hospital procedure-related 
bleeding, % 2.7% 3.2% 2.9% 
<0.001 
In-hospital thoracic complications, 
% 2.4% 3.8% 3.0% 
<0.001 
In-hospital cardiac complications, % 0.3% 0.5% 0.4% <0.001 
Device-related infection, %* 1.1% 0.6% 0.9% <0.001 
Table 3. Clinical Outcomes according to sex and type of CIED 
Outcome/Study Group  Male Female Total p-value 
In-hospital MACE, %*     
PPM, % 4.6% 5.8% 5.2% <0.001 
CRT-P, % 7.3% 6.6% 7.0% 0.001 
CRT-D, % 4.7% 5.1% 4.8% <0.001 
ICD, % 4.0% 4.8% 4.2% <0.001 
In-hospital all-cause 
mortality, % 
    
PPM, % 1.0% 1.2% 1.1% <0.001 
CRT-P, % 1.6% 1.0% 1.4% <0.001 
CRT-D, % 0.8% 0.6% 0.8% <0.001 
ICD, % 0.6% 0.7% 0.6% <0.001 
Procedure-related bleeding, 
% 
    
PPM, % 3.3% 3.4% 3.4% <0.001 
CRT-P, % 3.6% 3.3% 3.4% 0.041 
CRT-D, % 1.8% 2.1% 1.9% <0.001 
ICD, % 2.0% 2.5% 2.2% <0.001 
In-hospital thoracic 
complications, % 
    
PPM, % 2.6% 4.0% 3.3% <0.001 
CRT-P, % 4.1% 4.4% 4.2% 0.090 
CRT-D, % 2.3% 3.3% 2.6% <0.001 
ICD, % 2.0% 2.9% 2.2% <0.001 
In-hospital cardiac 
complications, % 
    
PPM, % 0.3% 0.4% 0.4% <0.001 
CRT-P, % 0.4% 0.6% 0.5% 0.026 
CRT-D, % 0.3% 0.6% 0.3% <0.001 
ICD, % 0.3% 0.6% 0.4% <0.001 
Device-related infection, %*     
PPM, % 0.9% 0.5% 0.7% <0.001 
CRT-P, % 1.8% 1.1% 1.5% <0.001 
CRT-D, % 1.6% 0.9% 1.4% <0.001 
ICD, % 1.3% 0.8% 1.2% <0.001 
*MACE: Composite of mortality, thoracic complications, cardiac complications and device-related infection; 
ICD: implantable cardioverter-defibrillator; CRT-P & CRT-D: cardiac resynchronization therapy - pacemaker 
or - defibrillator, respectively; PPM: permanent pacemaker.  
 
Table 4. Adjusted odds of adverse outcomes in women  
Frailty Risk 
Group/Outcome MACE* All-cause Mortality 
Procedure-related 
Bleeding Thoracic Complications Cardiac Complications 
 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 




Male** - - - - - - - - - - 
Female 1.17 [1.16, 1.19] <0.001 0.96 [0.94, 1.00] 0.198 1.13 [1.12, 1.15] <0.001 1.42 [1.40, 1.44] <0.001 1.44 [1.38, 1.50] <0.001 
PPM 
Male** - - - - - - - - - - 
Female 1.25 [1.23, 1.27] <0.001 1.01 [0.98, 1.05] 0.367 1.10 [1.08, 1.12] <0.001 1.49 [1.46, 1.52] <0.001 1.37 [1.30, 1.44] <0.001 
CRT-P 
Male** - - - - - - - - - - 
Female 0.91 [0.85, 0.97] 0.005 0.70 [0.60, 0.82] <0.001 1.01 [0.92, 1.11] 0.872 1.04 [0.95, 1.12] 0.424 1.06 [0.84, 1.35] 0.610 
CRT-D 
Male** - - - - - - - - - - 
Female 1.06 [1.02, 1.10] 0.003 0.72 [0.66, 0.80] <0.001 1.21 [1.15, 1.28] <0.001 1.38 [1.32, 1.45] <0.001 1.65 [1.47, 1.85] <0.001 
ICD 
Male** - - - - - - - - - - 
Female 1.07 [1.04, 1.10] <0.001 1.05 [0.97, 1.13] 0.252 1.23 [1.18, 1.28] <0.001 1.28 [1.23, 1.33] <0.001 1.59 [1.46, 1.73] <0.001 
*MACE: Composite of mortality, thoracic complications, cardiac complications and device-related infection; ICD: implantable cardioverter-defibrillator; CRT-P & CRT-
D: cardiac resynchronization therapy - pacemaker or - defibrillator, respectively; PPM: permanent pacemaker.  
 







